303 related articles for article (PubMed ID: 8163696)
21. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.
Saccani Jotti G; Johnston SR; Salter J; Detre S; Dowsett M
J Clin Pathol; 1994 Oct; 47(10):900-5. PubMed ID: 7962603
[TBL] [Abstract][Full Text] [Related]
22. pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer.
Correale M; Abbate I; Paradiso A; Schittulli F; Dragone CD; Tedone T; Gargano G; Catino AM; Musci MD; De Lena M
Cell Biophys; 1993; 22(1-3):101-10. PubMed ID: 7889536
[TBL] [Abstract][Full Text] [Related]
23. Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.
Soubeyran I; Quénel N; Mauriac L; Durand M; Bonichon F; Coindre J-M
Br J Cancer; 1996 Mar; 73(6):735-43. PubMed ID: 8611373
[TBL] [Abstract][Full Text] [Related]
24. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
25. Expression of pS2 protein in breast cancer.
Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ
Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of sex steroid receptors in breast cancer using routine paraffin sections: comparison with frozen sections and enzyme immunoassay.
Elias JM; Margiotta M; Sexton TR; Heimann A
J Cell Biochem Suppl; 1994; 19():126-33. PubMed ID: 7823584
[TBL] [Abstract][Full Text] [Related]
27. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
[TBL] [Abstract][Full Text] [Related]
28. Biphasic Scatchard plots of oestrogen receptors are associated with low pS2 levels in human breast cancers.
Marsigliante S; Biscozzo L; Leo G; Storelli C
Cancer Lett; 1999 Sep; 144(1):17-23. PubMed ID: 10503873
[TBL] [Abstract][Full Text] [Related]
29. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
[TBL] [Abstract][Full Text] [Related]
30. pS2 protein and steroid hormone receptors in invasive breast carcinomas.
Koerner FC; Goldberg DE; Edgerton SM; Schwartz LH
Int J Cancer; 1992 Sep; 52(2):183-8. PubMed ID: 1521907
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
Luqmani YA; Campbell T; Soomro S; Shousha S; Rio MC; Coombes RC
Br J Cancer; 1993 Apr; 67(4):749-53. PubMed ID: 8385977
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of pS2 mRNA in breast cancer.
Wysocki SJ; Iacopetta BJ; Ingram DM
Eur J Cancer; 1994; 30A(12):1882-4. PubMed ID: 7880621
[TBL] [Abstract][Full Text] [Related]
33. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].
Abadjian G; Antoun R
J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315
[TBL] [Abstract][Full Text] [Related]
34. [Receptor status (ER and PgR) determined with histochemical and biochemical methods in breast carcinoma].
Simone G; Paradiso A; Cirillo R; Mangia A; Rella G; Wiesel S; Petroni S; De Benedictis G; De Lena M
Pathologica; 1991; 83(1086):449-59. PubMed ID: 1724316
[TBL] [Abstract][Full Text] [Related]
35. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
[TBL] [Abstract][Full Text] [Related]
36. [Clinico-biological impact of pS2 positivity in estrogen receptor negative-infiltrating ductal carcinomas of the breast].
Ruibal A; Arias J; del Río MC; San Román JM; Lapeña G; Pardo C; Tejerina A
Rev Esp Med Nucl; 2000 Oct; 19(6):428-33. PubMed ID: 11060273
[TBL] [Abstract][Full Text] [Related]
37. [Expression of pS2-protein in breast cancer].
Kawabata K; Watanabe K; Ozaki S
Rinsho Byori; 1996 Jul; 44(7):647-52. PubMed ID: 8741495
[TBL] [Abstract][Full Text] [Related]
38. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
MacGrogan G; Mauriac L; Durand M; Bonichon F; Trojani M; de Mascarel I; Coindre JM
Br J Cancer; 1996 Nov; 74(9):1458-65. PubMed ID: 8912545
[TBL] [Abstract][Full Text] [Related]
39. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
[TBL] [Abstract][Full Text] [Related]
40. High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer.
Yamakawa T; Morimoto T; Sasa M; Numoto S; Monden Y
Jpn J Cancer Res; 1995 Nov; 86(11):1035-40. PubMed ID: 8567393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
